Literature DB >> 9706169

Primate renal transplants using immunotoxin.

S J Knechtle1, J H Fechner, Y Dong, S Stavrou, D M Neville, T Oberley, P Buckley, N Armstrong, K Rusterholz, X Hong, M Tsuchida, M M Hamawy.   

Abstract

BACKGROUND: T-lymphocyte depletion 7 days before transplantation with immunotoxin FN 18-CRM9 has resulted in tolerance to subsequent renal allografts. We tested the effect of giving immunotoxin on the day of the transplantation and evaluated its effect on rhesus monkey and allograft survival, on antibody production, and on T-cell recovery.
METHODS: Major histocompatibility complex mismatched renal allografts were performed in rhesus monkeys. Immunotoxin was given starting on the day of transplantation, with and without prednisone and mycophenolate mofetil for 3 days. T-cell subsets and alloantibody levels were measured by flow cytometry. The ability of treated monkeys to develop antibody to tetanus, diphtheria, and xenoantibody was measured. Histology of renal transplants was read in a blinded manner.
RESULTS: Immunotoxin started on the day of transplantation resulted in prolonged allograft survival in all treatment groups. Graft loss between days 50 and 135 was most often due to interstitial nephritis. Later graft loss was due to chronic rejection. Monkeys had intact antibody responses to alloantigen, tetanus, diphtheria, and xenoantibody. Their CD4 cells recovered gradually over 6 months.
CONCLUSIONS: Immunotoxin reliably prolongs renal allograft survival when started on the day of transplantation, but interstitial nephritis and chronic rejection limit the development of long-term tolerance. T-cell-dependent B-cell responses remain intact after treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706169

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

Review 1.  Challenges to achieving clinical transplantation tolerance.

Authors:  A D Salama; G Remuzzi; W E Harmon; M H Sayegh
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 2.  Lymphodepletional strategies in transplantation.

Authors:  Eugenia Page; Jean Kwun; Byoungchol Oh; Stuart Knechtle
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

3.  Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model.

Authors:  C A Huang; Y Fuchimoto; R Scheier-Dolberg; M C Murphy; D M Neville; D H Sachs
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 4.  Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation.

Authors:  Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2019-04-05       Impact factor: 3.943

Review 5.  Primate models in organ transplantation.

Authors:  Douglas J Anderson; Allan D Kirk
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

6.  Recombinant anti-monkey CD3 immunotoxin depletes peripheral lymph node T lymphocytes more effectively than rabbit anti-thymocyte globulin in naïve baboons.

Authors:  Isaac Wamala; Abraham J Matar; Evan Farkash; Zhirui Wang; Christene A Huang; David H Sachs
Journal:  Transpl Immunol       Date:  2013-10-22       Impact factor: 1.708

7.  Activation of cytomegalovirus in pig-to-primate organ xenotransplantation.

Authors:  Nicolas J Mueller; Rolf N Barth; Shin Yamamoto; Hiroshi Kitamura; Clive Patience; Kazuhiko Yamada; David K C Cooper; David H Sachs; Amitinder Kaur; Jay A Fishman
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Mixed chimerism and tolerance without whole body irradiation in a large animal model.

Authors:  Y Fuchimoto; C A Huang; K Yamada; A Shimizu; H Kitamura; R B Colvin; V Ferrara; M C Murphy; M Sykes; M White-Scharf; D M Neville; D H Sachs
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

9.  Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.

Authors:  Abraham J Matar; Vimukthi Pathiraja; Zhirui Wang; Raimon Duran-Struuck; Ashley Gusha; Rebecca Crepeau; Masayuki Tasaki; David H Sachs; Christene A Huang
Journal:  Transpl Immunol       Date:  2012-06-05       Impact factor: 1.708

Review 10.  Experimental modeling of desensitization: What have we learned about preventing AMR?

Authors:  Jean Kwun; Stuart Knechtle
Journal:  Am J Transplant       Date:  2020-06       Impact factor: 8.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.